Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:58 PM
Ignite Modification Date: 2025-12-24 @ 11:58 PM
NCT ID: NCT01286558
Eligibility Criteria: Inclusion criteria: 1. Essential hypertensive patients * If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be \>=90 and \>=114 mmHg * If not taking any antihypertensive drugs, mean seated DBP must be \>=95 and \>=114 mmHg 2. Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion. Exclusion criteria: 1. Patients taking 3 or more antihypertensive drugs at signing the informed consent form 2. Patients with known or suspected secondary hypertension 3. Patients with clinically relevant cardiac arrhythmia 4. Congestive heart failure with New York Heart Association (NYHA) functional class III-IV 5. Patients with recent cardiovascular events 6. Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form 7. Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy 8. Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors 9. Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs 10. Patients with hepatic and/or renal dysfunction 11. Pre-menopausal women who are nursing or pregnant
Sex: ALL
Minimum Age: 20 Years
Study: NCT01286558
Study Brief:
Protocol Section: NCT01286558